Are all cyclin-dependent kinases 4/6 inhibitors created equal?

The harnessing in clinical practice of cyclin-dependent kinases 4/6 inhibitors, namely palbociclib, ribociclib, and abemaciclib, has substantially changed the therapeutic approach for hormone receptor-positive metastatic breast cancer (BC). Phase II–III clinical trials evaluating the addition of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Marra, Antonio, Curigliano, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715721/
https://www.ncbi.nlm.nih.gov/pubmed/31482107
http://dx.doi.org/10.1038/s41523-019-0121-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715721/
https://www.ncbi.nlm.nih.gov/pubmed/31482107
http://dx.doi.org/10.1038/s41523-019-0121-y

Ejemplares similares